Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection

Here we describe the treatments and prognosis for metachronous metastases from gastroenteropancreatic neuroendocrine tumors (GEP-NETs) after initial R0 surgical resection at a large center in China. The clinicopathological data and survival outcomes for 108 patients (median age, 54.0 years) with met...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2019-04, Vol.19 (1), p.335-335, Article 335
Main Authors: Lv, Yang, Han, Xu, Xu, Xue-Feng, Ji, Yuan, Zhou, Yu-Hong, Sun, Hui-Chuan, Zhou, Jian, Fan, Jia, Lou, Wen-Hui, Huang, Cheng
Format: Article
Language:English
Subjects:
Ablation (Surgery)
Biological response modifiers
Cancer metastasis
Cancer patients
Cancer therapies
Care and treatment
Classification
Everolimus
Gastroenteropancreatic neuroendocrine tumor
Health aspects
Interferon
Liver
Liver diseases
Medical prognosis
Medical research
Metachronous liver metastasis
Metastases
Metastasis
Neuroendocrine tumors
Nomogram
Nomograms
Pancreas
Patients
Prognosis
Risk factors
Somatostatin
Sunitinib
Surgery
Survival
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Here we describe the treatments and prognosis for metachronous metastases from gastroenteropancreatic neuroendocrine tumors (GEP-NETs) after initial R0 surgical resection at a large center in China. The clinicopathological data and survival outcomes for 108 patients (median age, 54.0 years) with metachronous hepatic metastatic GEP-NETs disease who were initially treated using R0 surgical resection between August 2003 and July 2014 were analyzed using one-way comparisons, survival analysis, and a predictive nomogram. Fifty-five (50.9%) patients had pancreatic NETs and 92 (85.2%) had G2 primary tumors. For treatment of the hepatic metastases, 48 (44.4%) patients received liver-directed local treatment (metastasectomy, radiofrequency ablation, transcatheter arterial chemoembolization, etc.), 15 (13.9%) received systemic treatment (interferon, somatostatin analogs, etc.), and 45 (41.7%) received both treatments. Multivariable analyses revealed that OS was associated with hepatic tumor number (P 
ISSN:1471-2407
1471-2407
DOI:10.1186/s12885-019-5457-z